Cell free DNA has great potential as a biomarker for early detection of cancer as well as monitoring response to therapy in patients in a minimally invasive way. However, there are technical challenges that need to be considered before utilizing this technology in practice. This session discusses novel methodologies in early detection of cancer. It also addresses the frequency of clonal hematopoiesis inadvertently detected during cell-free DNA intended for solid tumor cancer patients, the importance evaluating matched white blood cells and the appropriate next steps when clonal hematopoiesis is detected as an incidental finding.
Clonal Hematopoiesis Detected from cfDNA Testing
Pedram Razavi, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
cfDNA to Detect and Characterize Cancer at Early Stages
Victor Velculescu, MD, PhD, John Hopkin's Medicine, Baltimore, MD, USA
Objectives:
- Describe ways in which cfDNA can be used for early cancer detection and challenges involved.
- Understand the frequency of clonal hematopoiesis inadvertently detected during cell-free DNA testing for solid tumors.
- Understand how clonal hematopoiesis can be distinguished from oncogenic mutations within cfDNA from solid tumor cancer cells.
Recording Date: November 18, 2020
Continuing Education Credit Information
CME/CMLE credit: 1.50 hr
Last day to purchase course and CE claim credit: February 16, 2024
Note: Members of AMP can access this at a discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
